Ambrx filed an Intent to Use trademark application with the USPTO for cancer treatment preparations comprising protein expression systems (amino acids, enzymes, RNA molecules, live cells). The goods description covers novel bio-therapeutics, bio-conjugated peptides, therapeutic proteins, monoclonal antibodies, and bi/multi-specific medicines under Nice Class 005 (Pharmaceuticals). Application TM90487620 was filed January 25, 2021.

This publication is informational for trademark monitoring purposes. Pharmaceutical companies developing similar therapeutic products should review clearance procedures to avoid potential conflicts. Investors tracking Ambrx's IP portfolio can note this cancer bio-therapeutics trademark filing as part of the company's intellectual property strategy. No immediate compliance action is required from other market participants unless they seek to oppose the registration.